This page provides links to presentations at scientific/medical society meetings. Those designated as webcasts include audio of the speaker, plus visuals of the slides shown by the speaker (almost like being there!) and a few also offer video of the speaker. Those designated as slide shows provide only the visual aids used by the speaker, without any voice. By studying the slides, you can still get a lot of information, even though it is not explained.
Note that some of the webcasts may not work in browsers other than Internet Explorer.
| New Challenges in Treating GIST: Which Target, What Agent, How Much, and When to Treat? |
| This is a webcast of a Novartis-sponsored ME seminar held in January 2008. The presenters and panelists are: George Demetri, MD; Burton Eisenberg, MD;, and Ronald DeMatteo, MD. You must register (for free) to watch the webcasts. You can also download Dr. Demetri's slides. |
| RECIST and Choi criteria for response assessment (RA) in patients with inoperable and metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate. Cambridge GIST study group experience. |
| Presenter: Venkata R Bulusu, MD, MSc.
2007 ASCO Annual Meeting abstract 10019. Click icon under "Associated Presentation" below abstract. |
| Pathological significance of deletions involving codons 557 and 558 of KIT gene in localized resected gastrointestinal stromal tumors (GIST) of intermediate and high risk: a study by the Spanish Group for Sarcoma Research (GEIS). |
| Presenter: Ignacio Romero, MD. 2007 ASCO Annual Meeting abstract 10051. Click icon under "Associated Presentation" below abstract. |
| Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase I trial. |
| Presenter: George D Demetri, MD. 2007 ASCO Annual Meeting abstract 10024. Click icon under "Associated Presentation" below abstract. |
| Subpopulation analyses in a worldwide treatment-use trial of sunitinib (SU) in GIST patients (pts) with resistance or intolerance to prior imatinib (IM) therapy. |
| Presenter: Peter Reichardt, MD. 2007 ASCO Annual Meeting abstract 10022. Click icon under "Associated Presentation" below abstract. |
| Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. |
| Presenter: Suzanne George, MD. 2007 ASCO Annual Meeting abstract 10015. Click icon under "Associated Presentation" below abstract.
|
| Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts). |
| Presenter: Martine M Van Glabbeke, PhD
2007 ASCO Annual Meeting abstract 10004
|
| Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 |
| Speaker: Ronald DeMatteo, MD
2007 ASCO Annual Meeting abstract 10079
Click icon under "Associated Presentation" below the abstract.
|
| A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update. |
| Presenter: Margaret Von Mehren, MD
2007 ASCO Annual Meeting
|
| Rare incidence of congestive heart failure (CHF) in gastrointestinal stromal tumor (GIST) and other sarcoma patients (pts) receiving imatinib mesylate (IM) therapy. |
| Presenter: Aarif Y Khakoo, MD
2007 ASCO Annual Meeting abstract 10026 |
| Interruption of imatinib (IM) in GIST patients with advanced disease after one year of treatment: Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. |
| Presenter: Maria RIOS, MD
2007 ASCO Annual Meeting abstract 10016
|
| Evaluation of soluble KIT (sKIT) as a potential surrogate marker for TTP in sunitinib malate (SU)-treated patients (pts) with advanced GIST. |
| Presenter: Martin Blackstein, MD, PhD
2007 ASCO Annual Meeting abstract 10007
|
| Relationship between compliance with imatinib mesylate and medical costs for patients with CML and GIST. |
| Presenter: Rachel Halpern, PhD, MPH
2007 ASCO Annual Meeting abstract 6618 |
| Perioperative morbidity in metastatic gastrointestinal stromal tumors (GIST) undergoing surgery of residual disease following imatinib (IM). |
| Presenter: Alessandro Gronchi, MD
2007 ASCO Annual Meeting abstract 10043 |
| Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs). |
| Presenter: Michael C Heinrich, MD
2007 ASCO Annual Meeting abstract 10006 |
| Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group |
| Presenter: Axel Le Cesne, MD
2007 ASCO Annual Meeting abstract 10016
|
| Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs). |
| Presenter: Dan M Byrd, MD
2007 ASCO Annual Meeting, abstract 10054 |
| Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors. |
| Presenter: Chandrajit P Raut, MD, MSc
2007 ASCO Annual Meeting abstract 10044 |
| Treatment Update on GIST |
| Presenters: Michael Heinrich, MD and George Demetri, MD
Teleconference recording from January 2007, sponsored by CancerCare. |
| Molecular Targeted Therapies and Diagnostics in GIST: Lessons Learned in Clinical Development. |
| Presenter: George Demetri, MD (October 2006).
This webcast from The DAVE Project is a lecture by Dr. Demetri to gastroenterology residents.
|
| The DAVE Project film of gastric GIST. |
| This narrated film clip shows the endoscopic view of a gastric GIST.
It was produced by Doctors PS Sepe & PB Kelsey of Massachusetts General Hospital. |
| GIST: The Use of Detailed Mutational Analysis to Guide Therapy |
| Presentation by Charles Blanke, MD.
January 2007 ASCO Gastrointestinal Cancers Symposium.
Webcast or slides (your choice).
Click the "video" or "slides" icon to the right of the name Charles Blanke on the linked page. |
| Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Results of a phase I trial. |
| Presenter: George D. Demetri, MD.
January 2007 ASCO Gastrointestinal Cancer Symposium.
View as slides OR listen as webcast.
Click desired icon "slides" or "video" at #2 below abstract. |
| CancerCare teleconference audio archive |
| The organization CancerCare, sponsored by Pfizer Oncology, presented an important educational opportunity for GIST patients and their families. CancerCare held a FREE telephone educational workshop on January 30, 2007. Oncologists Michael Heinrich, MD and George Demetri, MD were the speakers.
"Treatment Update on GIST"
Access a replay of the one-hour teleconference at this link:
|
| Third GIST Global Opinion Leader Summit |
| Educational materials from the Third GIST Global Opinion Leader Summit meeting, "Multi-modality Approaches to Treating Patients with GIST" are available at a website set up for their distribution. This meeting, held in Prague on October 27-29, 2006, was supported by an unrestricted grant from Novartis Oncology. The co-chairs for the meeting were Jean-Yves Blay, MD PhD and Peter Reichardt, MD PhD, both well-known GIST experts.
There are numerous presentations covering many GIST topics available at this website link, and the user can choose either to view the presentations as webcasts (listening to the speakers) or to view only the slides (no audio). |
| Multitargeted Agents Show Promise for Improving Outcomes in the Treatment of Solid Tumors |
| by Robert A. Figlin, MD
Presented 2006 or University of Florida & "PeerView in Review" |
| Expanding Role of Multitargeted Agents in the Treatment of Gastrointestinal Stromal Tumors |
| by Michael C. Heinrich, MD
Presented 2006 at University of Florida. |
| Current Therapies Improve Outcomes for Patients with Gastrointestinal Stromal Tumors |
| by Charles D. Blanke, MD
presented 2006 or University of Florida & Peer View in Review |
| New Treatments Active in Imatinib-Resistant Gastrointestinal Stromal Tumors |
| by Margaret von Mehren, MD
presented 2006 sponsored by University of Florida & PeerView in Review |
| Current Clinical management of GIST: Maintaining Disease Control |
| by Robert Maki, MD
presented December 2005 for University of Florida & Peer View in Review |
| Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. |
| Presenter: Michael C. Heinrich. MD
ASCO 2006 abstract 9502, viewable either as webcast or as slide show.
Click desired presentatoin icon beneath abstract to view. |
| Do patients with initially resected metastatic GIST benefit from 'adjuvant' imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial. |
| Presenter: Binh N. Bui, MD
ASCO 2006 abstract 9501, viewable either as webcast or as slide show.
Click desired presentation icon beneath abstract to view. |
| Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST). |
| Presenter: Peter Hohenberger, MD
ASCO 2006 abstract 9500, viewable either as webcast or as slide show.
Click desired presentation icon beneath abstract to view. |
| Response of gastrointestinal stromal tumors (GISTs) to imatinib by Choi criteria and response evaluation criteria in solid tumors (RECIST) as surrogates for survival and time to progression. |
| Presenter: Robert S. Benjamin, MD
ASCO 2006 abstract 9506, viewable either as webcast or as slide show.
Click desired presentation icon beneath abstract to view. |
| Discussion segments, session "Gastrointestinal Stromal Tumors: Multimodal Approach" |
| From the linked page you can select from discussion segments led by the following discussants:
Discussion leaders:
1) George Demetri, MD
2) Chandrajit Raut, MD
3) Margaret von Mehren, MD
4) Ian Judson, MD
ASCO 2006, discussion webcasts available, as well as slides shown by discussants.
Click the desired icon to the right of the discussant's name. |
| Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. |
| Presenter: Katherine Janeway, MD
ASOC 2006 abstract 9519, slide show. Click "slides" icon beneath abstract to view slides. |
| Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST |
| Presenter: Suzanne George, MD
ASCO 2006 abstract 9532, slide show. Click "slides" icon beneath abstract to view. |
| Loss of heterozygosity with acquisition of homozygous KIT-activating mutation promotes gastrointestinal stromal tumor progression. |
| Presenter: Lei L. Chen, MD PhD
ASCO 2006 abstract 9530, slide show. Click "slides" icon beneath abstract to view. |
| Familial gastrointestinal stromal tumor with homo-/hemizygous kit exon 11 deletion: Genotypic, histopathologic, radiographic, and therapeutic findings. |
| Presenter: Eric P. Kleinbaum
ASCO 2006 abstract 9527, poster. Click "slides" icon beneath abstract. (Note that this will show a single image of the entire poster, so it is very small and hard to read.) |
| Evaluation of SRC-family kinases in gastrointestinal stromal tumors. |
| Presenter: Sebastian Bauer, MD
ASCO 2006 abstract 9529, slide show. Click "slides" icon beneath abstract. |
| A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. |
| Presenter: Heikki Joensuu. MD
ASCO 2006 abstract 9531, slide show. Click "slides" icon beneath abstract. |
| Surgical interventions for focal progression of gastrointestinal stromal tumors under imatinib therapy. |
| Presenter: Toshirou Nishida, MD PhD
ASCO 2006 abstract 9548, slide show. Click "slides" icon beneath abstract. |
| reGISTry: An observational registry of gastrointestinal stromal tumor (GIST) patients (pts) in the USA. |
| Presenter: Jonathan C Trent, MD
ASCO 2006 slide show of abstract 9543. Click "slides" icon beneath abstract. |
| Pediatric GIST: the new kid on the block. |
| Presenter: Alberto S. Pappo, MD
ASCO 2006 presentation viewable as webcast only (not as slide show).
Click video icon on linked page. |
| Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. |
| Presenter: Paolo Casali. MD
ASCO 2006 presentation viewable as webcast or slide show. |
| Increase of creatine kinase value (CK) correlates with muscoloskeletal complaints (MSC) in GIST patients during imatinib therapy. |
| Presenter: Paolo Allione, MD
ASCO 2006. Viewable as webcast or as slide show. |
| Anti-VEGF Therapy for Solid Malignancies: Clinical Results and Surgical Issues |
| Presenter: Lee M. Ellis, MD
Slide show from Society of Surgical Oncology meeting, March 2006 |
| Improved survival and sustained clinical benefit with SU11248 (SU) in pts with GIST after failure of imatinib mesylate therapy in a phase III trial |
| Presenter: George Demetri, MD
Webcast from ASCO Gastrointestinal Cancers Symposium, January 2006.
After clicking link, then click the "VIDEO" icon to the right of Dr. Demetri's name. |
| Outcome of advanced GIST patients treated with imatinib mesylate: four-year follow-up of a randomized Phase II trial |
| Presenter: Charles Blanke, M.D.
ASCO Gastrointestinal Cancer Symposium, January 2006
Webcast (slides plus audio) available. After clicking the link, then click the "VIDEO" icon to the right of Dr. Blanke's name. |
| Surgical management of advanced GIST following KIT-directed therapy |
| Authors: CP Raut, M Posner, J Desai, GD Demetri, JA Morgan, S George, D Zahrieh, CDM Fletcher, MM Bertagnolli
Slide show presented at CTOS, November 2005 (requires Powerpoint viewer) |
| Targeting HSP90 in imatinib-resistant GIST |
| Authors: S Bauer, L Yu, GD Demetri, JA Fletcher
Slide show presented at CTOS, November 2005 (requires Powerpoint viewer) |
| Advanced Gastrointestinal stromal tumor: molecular, pathological and clinical pattern in post-imatinib surgery |
| Authors: A Gronchi, M Fiore, R Bertulli, E Tamborini, P Collini, S Pilotti, C Mussi, P Coco, A Messina, S Stacchiotti, PG Casali
Slide show from CTOS, November 2005 (requires Powerpoint viewer, slow download) |
| The Era of Molecularly Targeted Therapy: redefining the treatment of GIST |
| Presenter: Gianluca Fincato, MD
Western Europe Medical Affairs Director, Novartis
Date: June 2005, Dublin Ireland
Meeting: "New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST" |
| Summary of ESMO Consensus on GIST and current research |
| Presenter: Peter Reichardt, MD
Date: June 2005, Dublin Ireland
Meeting: "New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST" |
| Special Plenary Lecture: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GISTs |
| Presenter: Michael C. Heinrich, MD
ASCO, May 2005
After clicking the link, click "Audio & Slides (below the abstract) to view presentation. |
| Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST) |
| Presenter: Annick D. Van den Abbeele, MD
ASCO. May 2005
After clicking the link, click either "Video" (to hear the talk) or "Slides" (to see slides without audio). |
| Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST |
| Presenter: George D. Demetri, MD
ASCO, May 2005
After clicking link, click "video" to hear and view presentation. |
| Apoptotic and anti-vascular activity of imatinib in GIST patients |
| Presenter: Jonathan C. Trent, MD
AACO May 2005
Ater clicking link, click "Video" to hear and view presentation. |
| Results from a continuation trial of SU11248 in patients with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) |
| Presenter: Robert G. Maki, MD, PhD
ASCO, May 2005
After clicking the link, click either "Video" (to hear the talk) or "Slides" (to see slides without audio). |
| Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S003 |
| Presenter: Martin E Blackstein, MD, PhD, FACP
ASCO, May 2005
After clicking the link, click either "Video" (to hear the talk) or "Slides" (to see slides without audio). |
| Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results |
| Presenter: Ronald P. DeMatteo, MD
ASCO, May 2005
After clicking the link, click either "Video" (to hear the talk) or "Slides" (to see slides without audio). |
| FDG PET but not RECIST agrees with histologic response of soft tissue sarcoma to neoadjuvant chemotherapy |
| Presenter: Scott M. Schuetze, MD, PhD
ASCO, May 2005
After clicking the link, click "Video" to hear and view presentation. |
| Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors |
| Presenter: Lee Rosen, MD
ASCO, May 2005
After clicking the link, click "Video" to hear and view presentation. |
| Pharmacodynamic analysis of target receptor tyrosine kinase activity and apoptosis in GIST tumors responding to therapy with SU11248 |
| ASCO, May 2005
Presenter: Darren W. Davis, Ph.D.
After clicking the link, click "Video" to hear and view presentation. |
| Rational Treatment Options for GIST: Gleevec, SU11248, RAD001 and Beyond |
| Webcast of presentation made in November 2004
by George D. Demetri, M.D.
at the Chemotherapy Foundation Symposium and Online Education Program, Mount Sinai School of Medicine.
After linking to the MSSM site, scroll down to the GI Cancers section and click beside the presentation title for Dr. Demetri's talk. |
| Systemic Management of Primary GIST |
| Webcast presented by Peter Reichardt, M.D.
in April 2004 to the Chinese Society of Clinical Oncology.
After linking to CSCO site, scroll down to the 11:10 am time slot on Saturday and click the link for Dr. Reichardt's presentation. |
| GIST - Current and Future Clinical Trials |
| Milind Javle, MD
Slide presentation at the November 2004 NCCN GIST conference, Roswell Park Cancer Institute. |
| 18F-FDG PET -- a metabolic tool to grade treatment response in advanced gastrointestinal stromal tumor (GIST) |
| Dominick Lamonica, MD RPCI
Slide show presented at the November 2004 NCCN conference on GIST, Roswell Park Cancer Institute. |
| Staging and surgical therapy for primary and recurrent gastrointestinal stromal tumors |
| John M. Kane III, MD
Slide presentation at the Nov. 2004 NCCN GIST conference, Roswell Park Cancer Institute. |
| The pathology of gastrointestinal stromal tumors |
| Charles M. LeVea, MD PhD
Slide show presented at the November 2004 NCCN conference on GIST, Roswell Park Cancer Institute. |
| Medical management of GIST |
| Michael Morse, MD
This slide show was presented at the November 2004 NCCN GIST conference, Roswell Park Cancer Institute. |
| Interactive Tumor Board: Case no. 1: Gastric GIST |
| Benjamin F. Calvo, MD
slide show presented at the October 2004 annual clinical congress, American College of Surgeons |
| Localized GIST in the Gleevec Era |
| Slide show by Ronald P. DeMatteo, M.D.
at the October 2004 Annual Clinical Congress, American College of Surgeons |
| Prognostic factors for initial and late resistance to imatinib in patients with advanced GIST |
| Van Glabbeke M et al (group of authors from EORTC-ISG-AGIGT)
Slides (in Powerpoint software) from presentation at the Connective Tissue Oncology Society meeting, Nov. 2004. |
| Acquired resistance to imatinib in GIST due to multiple kinase-domain mutations of KIT |
| Slides presented by Wardelmann et al
PowerPoint slides from Connective Tissue Oncology Society, Nov. 2004
Note that this may take a long time to download. |
| A comparison of patterns of tumor response to molecular-targeted therapy in GIST and chordoma |
| Casali et al
Powerpoint slides from presentation at CTOS, Nov, 2004 |
| The management of gastrointestinal stromal tumors and Recognizing and managing resistance to imatinib mesylate in patients with metastatic GIST |
| This webcast by Charles D. Blanke, MD was presented
on 6/19/2004 at the World Congress on Gastrointestinal Cancer.
It consists of two papers webcast back-to-back.
The second part was authored by George Demetri, MD, but Dr. Blanke gave the oral presentation in Dr. Demetri's absence.
NOTE that this webcast will not play in some browsers but does work fine in Internet Explorer. |
| Molecular events in gastrointestinal stromal tumors |
| This webcast was presented by Maria Debiec-Rychter, MD PhD
on 6/19/2004 at the World Congress on Gastrointestinal Cancer.
NOTE that this webcast works fine in Internet Explorer but does not play in some other browsers. |
| Is a PET scan a necessary tool in the treatment of gastrointestinal stromal tumors? |
| This webcast by Sigrid Stroobrants, MD PhD was presented
on 6/19/2004 at the World Congress on Gastrointestinal Stromal Tumors.
NOTE that this webcast works in Internet Explorer but does not play in some other browsers. |
| Long-term followup of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate |
| Webcast presentation by Charles Blanke, MD
ASCO 2004 Gastrointestinal Cancers Symposium
Once you have linked to the ASCO site, click the icon for "Video" to start the webcast. |
| NCCN GIST Webcast |
| Dr. George Demetri and Dr. Ronald DeMatteo are this presenters in this comprehensive webcast summarizing a task force report from the National Comprehensive Cancer Network.
This webcast has been removed from the NCCN site. A limited number of copies of a CD-ROM containing the webcast may be available through NCCN. |
| Imatinib may enable complete resection in previously unresectable or metastatic GIST. |
| Presenter: Sebastian Bauer, MD
ASCO 2004 meeting abstract 9023
Link to AASCO site, then click "Slides" icon (look below abstract) to view slides. |
| SU11248 can overcome imatinib resistance caused by diverse genomic mechanisms in patients with metastatic GIST |
| Presenter: George D. Demetri, MD
ASCO 2004 annual meeting abstract 3001
After linking to the ASCO page, click "Video" to start webcast (look below the abstract). |
| Combination signal transduction inhibition: a phase I/II trial of ... RAD001 and imatinib in patients with GIST refractory to imatinib |
| Presenter:AT van Oosterom, MD PhD
2004 ASCO meeting abstract 3002
After linking to the ASCO page, click "Video" icon to start webcast (look below the abstract). |
| Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SUO11248 in patients with metastatic GIST refractory to imatinib mesylate |
| Presenter: Jayesh Desai, MD
ASCO 2004 Gastrointestinal Cancers Symposium abstract 7
After linking to ASCO page, click "video" icon to play the webcast (look below the abstract). |
| Gastrointestinal Stromal Tumors |
| Presenter: AT van Oosterom, MD PhD
ASCO 2004 annual meeting.
Link to ASCO, then click icon for "Video" under the listing numbered as
"2. Gastrointestinal Stromal Tumors." |
| Emerging Issues: biology and management of GIST |
| Presenter: S. Patel, MD
ASCO 2004 annual meeting
Link to the ASCO site, then scroll down the page to the last discussion entry by Dr. Patel, then click "Video" to the right of Dr. Patel's name to play the lecture. |
| p53 mutations in GIST: pattern and prognostic significance |
| Presenter: M-H Ryu, MD
2004 ASCO meeting abstract 9026
Link to the ASCO page, then click "Slides" icon below the abstract to view slides (no sound). |
| Use of CT as an early prognostic indicator of response to imatinib mesylate in patients with GIST |
| Presenter: CH Holdsworth, PhD
2004 ASCO meeting abstract 3011.
Link to ASCO site, then click "slides" to view. |
| Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic GIST with clonal evolution of lesions refractory to imatinib |
| Presenter P. Dileo, MD
2004 ASCO meeting abstract 9024
Link to ASCO site, then click "slides" to view (look below abstract). |
| Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of GIST, a GEIS study |
| Presenter: J. Martin, MD
2004 ACSO meeting abstract 9029
Link to ASCO site, then click "slides" icon (look below abstract) to view. |
| Effects of cessation of imatinib mesylate therapy in patients with imatinib-refractory GIST as visualized by FDG-PET scanning |
| Slide presentation by AD Van den Abbeele, MD
ASCO 2004 meeting abstract 3012
Link to ASCO site, then click "slides" icon (look below abstract) to view. |
| Clonal evolution of resistance to imatinib in patients with GIST: molecular and radiologic evaluation of new lesions |
| Presenter: Jayesh Desai, MD
ASCO 2004 meeting abstract 3010
Link to ASCO site, then click "slides" icon (look below abstract) to view. |
| Risk estimation with tumor size, serosal invasion and MIB-1 labeling index for GIST of the stomach |
| Slide presentation by H. Cho, MD
at 2004 ASCO meeting.
Link to ASCO site, then click "slides" to view. |
| ASCO 2003 Session on Sarcoma |
| This session includes several presentations on GIST.
Link to the ASCO site, then scroll down the page to find and select the desired presentations from this list.
Sarcoma
Robert G Maki, MD, PhD (Discussant)
Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results.
Abstract No: 3271
Robert S Benjamin, MD
Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): Interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG.
Abstract No: 3272
Jaap Verweij, MD, PhD
Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate.
Abstract No: 3273
George D. Demetri, MD
PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors (GIST)
Abstract No: 3274
Michael C Heinrich, MD
Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST)
Abstract No: 3275
Jonathan A. Fletcher, MD
Below is the link to view the ASCO page containing the above presentation links: |
| Therapeutic options for gastrointestinal stromal tumors |
| Presenter: Charles D. Blanke, MD
ASCO 2003 meeting.
Link to the ASCO site, then click "Video" (look below abstract) to start webcast. |
| Gastrointestinal stromal tumors: diagnosis, epidemiology, prognosis |
| Presenter: L-G Kindblom, MD
ASCO 2003 meeting.
Link to the ASCO site, then click "Video" (look to right of Dr. Kindblom's name)to start the webcast. |
| Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal |
| Presenter: GD Demetri, MD
ASCO 2003 meeting abstract 3273.
Link to ASCO and click "slides" to view (look below abstract). |
| Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) |
| Presenter: JA Fletcher, MD
ASCO 2003 meeting abstract 3275.
Link to ASCO, then click "slides" to view (look below abstract). |
| STI-571 in GI Stromal Tumors |
| Presenter: George D. Demetri, MD
2001 Chemotherapy Foundation Symposium and Online Education Program, Mount Sinai School of Medicine.
After linking to the MSSM site, scroll down to the "Novartis" section of the program and you will see the clicker to view the presentattion for Dr. Demetri. |
| Clinical Management of GIST: Understanding the New Paradigms |
| This is a CME publication covering key clinical issues in the management of GIST including highlights from the 2003 Connective Tissue Oncology Society annual meeting and the Helsinki Gist Symposium. It was released in April 2004. While not strictly a slide show, this booklet contains graphics from many different presentations by experts. |
| Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI-571, in patients with unresectable or metastatic GISTs |
| Presenter: Charles Blanke, MD
ASCO 2001 meeting plenary lecture.
This was the first presentation about Gleevec trials for GIST.
Link to ASCO site, click "Video" to start the webcast (look to the right of Dr. Blanke's name). |
We subscribe to the HONcode principles. 
